Flash FinanceUS
Market closed S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Alkermes (ALKS)

Alkermes says preliminary 2025 commercial revenue topped $1.45 billion

Neutral Impact 3 of 5 earnings Written later

Alkermes furnished a corporate presentation for the J.P. Morgan Healthcare Conference that includes preliminary, unaudited estimated total revenues for 2025. The filing says these figures may change after the company completes its year-end financial statement review, and it gives no prior-year comparison or profit figures.

Key points

  • Presentation states the commercial business generated total revenues above $1.45 billion in 2025.
  • Revenue figures are preliminary and unaudited and subject to change after the year-end review.
  • Presentation was made available January 12, 2026, for a J.P. Morgan Healthcare Conference presentation on January 13, 2026.
  • The planned Avadel acquisition is expected to close in Q1 2026.

The filing

CompanyAlkermes (ALKS)
Form8-K, current report
Filed with the SECJan 12, 2026, 8:00 AM ET
Accession number0001193125-26-009813

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 12:57 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on January 12, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.